Literature DB >> 28721305

Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use.

Irina Velikyan1,2, Ulrika Rosenstrom1, Olof Eriksson1.   

Abstract

[68Ga]Ga-DO3A-VS-Cys40-Exendin-4/PET-CT targeting glucagon like peptide-1 receptor (GLP-1R) has previously demonstrated its potential clinical value for the detection of insulinomas. The production and accessibility of this radiopharmaceutical is one of the critical factors in realization of clinical trials and routine clinical examinations. Previously, the radiopharmaceutical was prepared manually, however larger scale of clinical trials and healthcare requires automation of the production process in order to limit the operator radiation dose as well as improve tracer manufacturing robustness and on-line documentation for enhanced good manufacturing practice (GMP) compliance. A method for 68Ga-labelling of DO3A-VS-Cys40-Exendin-4 on a commercially available synthesis platform was developed. Equipment such as 68Ge/68Ga generator, synthesis platform, and disposable cassettes for 68Ga-labelling used in the study was purchased from Eckert & Ziegler. DO3A-VS-Cys40-Exendin-4 was synthesized in-house. The parameters such as time, temperature, precursor concentration, radical scavenger, buffer concentration, pH, product purification step were investigated and optimised. Reproducible and GMP compliant automated production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 was developed. Exendin-4 comprising methionine amino acid residue was prone to oxidation which was strongly influenced by the elevated temperature, radioactivity amount, and precursor concentration. The suppression of the oxidative radiolysis was achieved by addition of ethanol, dihydroxybenzoic acid and ascorbic acid to the reaction buffer as well as by optimizing heating temperature. The non-decay corrected radiochemical yield was 43±2% with radiochemical purity of over 90% wherein the individual impurity signals in HPLC chromatogram did not exceed 5%. Automated production and quality control methods were established for paving the pathway for broader clinical use of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4.

Entities:  

Keywords:  Exendin-4; GLP-1; GMP; Gallium-68; Insulinoma; automation

Year:  2017        PMID: 28721305      PMCID: PMC5511121     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  36 in total

1.  Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.

Authors:  Emanuel Christ; Damian Wild; Kwadwo Antwi; Beatrice Waser; Melpomeni Fani; Stefanie Schwanda; Tobias Heye; Christoph Schmid; Hans Ulrich Baer; Aurel Perren; Jean Claude Reubi
Journal:  Endocrine       Date:  2015-05-23       Impact factor: 3.633

2.  Oxidation of methionine - is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?

Authors:  Barbara Janota; Urszula Karczmarczyk; Ewa Laszuk; Piotr Garnuszek; Renata Mikołajczak
Journal:  Nucl Med Rev Cent East Eur       Date:  2016

3.  Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.

Authors:  Damian Wild; Emanuel Christ; Martyn E Caplin; Tom R Kurzawinski; Flavio Forrer; Michael Brändle; Jochen Seufert; Wolfgang A Weber; Jamshed Bomanji; Aurel Perren; Peter J Ell; Jean Claude Reubi
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

4.  Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.

Authors:  Maarten Brom; Wietske Woliner-van der Weg; Lieke Joosten; Cathelijne Frielink; Thomas Bouckenooghe; Paul Rijken; Karolina Andralojc; Burkhard J Göke; Marion de Jong; Decio L Eizirik; Martin Béhé; Tony Lahoutte; Wim J G Oyen; Cees J Tack; Marcel Janssen; Otto C Boerman; Martin Gotthardt
Journal:  Diabetologia       Date:  2014-02-01       Impact factor: 10.122

5.  Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Authors:  Irina Velikyan; Anders Wennborg; Joachim Feldwisch; Henrik Lindman; Jörgen Carlsson; Jens Sörensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24

6.  Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.

Authors:  Mark S Fineman; Larry Z Shen; Kristin Taylor; Dennis D Kim; Alain D Baron
Journal:  Diabetes Metab Res Rev       Date:  2004 Sep-Oct       Impact factor: 4.876

7.  Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.

Authors:  Olof Eriksson; Irina Velikyan; Ram K Selvaraju; Fouad Kandeel; Lars Johansson; Gunnar Antoni; Barbro Eriksson; Jens Sörensen; Olle Korsgren
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

8.  A fully automated synthesis for the preparation of 68Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger Knopp; Elisabeth von Guggenberg; Marco Rupprich; Thorsten Dreger; Andre Hess; Irene Virgolini; Roland Haubner
Journal:  Nucl Med Commun       Date:  2007-11       Impact factor: 1.690

Review 9.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

10.  99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.

Authors:  Anna Sowa-Staszczak; Małgorzata Trofimiuk-Müldner; Agnieszka Stefańska; Monika Tomaszuk; Monika Buziak-Bereza; Aleksandra Gilis-Januszewska; Agata Jabrocka-Hybel; Bogusław Głowa; Maciej Małecki; Tomasz Bednarczuk; Grzegorz Kamiński; Aldona Kowalska; Renata Mikołajczak; Barbara Janota; Alicja Hubalewska-Dydejczyk
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

View more
  10 in total

Review 1.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 2.  Good practices for 68Ga radiopharmaceutical production.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest; Sarah Spreckelmeyer
Journal:  EJNMMI Radiopharm Chem       Date:  2022-10-22

3.  Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs.

Authors:  Charles-Henri Malbert; Alain Chauvin; Michael Horowitz; Karen L Jones
Journal:  BMJ Open Diabetes Res Care       Date:  2020-11

4.  Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.

Authors:  Olof Eriksson; Irina Velikyan; Torsten Haack; Martin Bossart; Iina Laitinen; Philip J Larsen; Jan Erik Berglund; Gunnar Antoni; Lars Johansson; Stefan Pierrou; Joachim Tillner; Michael Wagner
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 10.057

5.  68Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers.

Authors:  Henri Baudhuin; Julie Cousaert; Philippe Vanwolleghem; Geert Raes; Vicky Caveliers; Marleen Keyaerts; Tony Lahoutte; Catarina Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10

6.  Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4.

Authors:  Olof Eriksson; Ulrika Rosenström; Ram K Selvaraju; Barbro Eriksson; Irina Velikyan
Journal:  Acta Diabetol       Date:  2017-09-11       Impact factor: 4.280

7.  Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4.

Authors:  Simon A M Kaeppeli; Roger Schibli; Thomas L Mindt; Martin Behe
Journal:  EJNMMI Radiopharm Chem       Date:  2019-05-16

Review 8.  Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.

Authors:  Irina Velikyan; Olof Eriksson
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

9.  Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.

Authors:  Olof Eriksson; Torsten Haack; Youssef Hijazi; Lenore Teichert; Veronique Tavernier; Iina Laitinen; Jan Erik Berglund; Gunnar Antoni; Irina Velikyan; Lars Johansson; Stefan Pierrou; Michael Wagner; Joachim Tillner
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

10.  Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method.

Authors:  Silvia Migliari; Antonino Sammartano; Marti Boss; Martin Gotthardt; Maura Scarlattei; Giorgio Baldari; Claudia Silva; Riccardo C Bonadonna; Livia Ruffini
Journal:  Molecules       Date:  2022-01-15       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.